Sports Card Blogs

Discovery to Clinical Supply; How Biosynth’s latest Acquisition

Peptides from Discovery to Clinical and Commercial Supply

The global peptide market is rapidly rising. It has been forecast that the peptide therapeutic market will reach USD 64.3 billion by 2031, growing at a CAGR of 6.8% from a value of USD 33.3 billion in 2021. This staggering statistic is largely down to the increasing recognition of peptides as revolutionary tools in drug discovery and development. Sitting in size between the classic small molecule drugs (SMDs) and the newer generation of biological drugs like monoclonal antibodies, peptides offer equal and even superior therapeutic properties to these well-established therapies. It is this dominance of peptides and the need to eliminate the rising incidence of cancer, as well as metabolic disorders such as osteoporosis, obesity and diabetes, that is driving the significant marker growth of peptides, with many companies investigating the development of new peptide drug candidates. 

Biosynth’s has built a peptide supply division unlike others to support drug development companies. This is focused around the whole of the peptide research, development, and commercialization process, across global sites and with the flexibility to meet the range of needs of those developing novel peptide-based treatments and diagnostics. 

During the recent CPHI event, Ehab Alramahy, Head of Peptide Division, sat down with the Medicine Maker to talk about how Biosynth address customer’s needs. 

Watch the full interview